Sebastian Faro, MD
Obstetrics & Gynecology · Houston, TXNPI 1356342315
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Janssen Research & Development, LLC at 53.5% of the total. Reporting peaked in 2022 at $980 and has fallen 85.2% since, to $145 in 2025.
Across 34 payments — averaging $53.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$980
- Sumitomo Pharma America, Inc.$154
- Mayne Pharma Commercial LLC$136
- Boston Scientific$107
- Astellas Pharma US Inc$106
- Caldera Medical, Inc$65
- plus $284 from 9 others
What the payments were for
- Consulting fees$98053%
- Food & beverage$85247%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 1 | $980 |
| Sumitomo Pharma America, Inc. | 6 | $154 |
| Mayne Pharma Commercial LLC | 6 | $136 |
| Boston Scientific | 1 | $107 |
| Astellas Pharma US Inc | 6 | $106 |
| Caldera Medical, Inc | 1 | $65 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Smith+Nephew | 2 | $43 |
| Exeltis, USA Inc. | 2 | $35 |
| Shield Therapeutics Inc | 2 | $31 |
| Gynesonics, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| AbbVie | 1 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,832 in reported general payments places this provider in the 65th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fosfomycin Tromethamine | 17 | $2,404 |
| Estradiol | 40 | $2,137 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $556 |
| Terconazole | 11 | $300 |
| Fluconazole | 25 | $221 |
| Ciprofloxacin Hcl | 12 | $69 |
| Triamcinolone Acetonide | 16 | $37 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Houston
- George KuhnHouston$244K
- Daisy AyimHouston$188K
- Shannon WestinHouston$176K
- Asha BhalwalHouston$151K
- Nicole TranHouston$133K
- Sandra HurtadoHouston$123K
- Alvaro MontealegreHouston$92K
- Patti RossHouston$72K
- Damla KarsanHouston$58K
- Christopher JayneHouston$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.